



Patient Name : Mr.JEEVAN DSOUZA
Age/Gender : 36 Y 11 M 18 D/M
UHID/MR No : CJPN.0000089496

Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801

 Collected
 : 25/Nov/2023 09:24AM

 Received
 : 25/Nov/2023 12:51PM

 Reported
 : 25/Nov/2023 02:38PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUAL	L PLUS MALE -	2D ECHO - PAN INDIA -	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

HAEMOGLOBIN	15.5	g/dL	13-17	Spectrophotometer
PCV	45.50	%	40-50	Electronic pulse & Calculation
RBC COUNT	5.04	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	90.4	fL	83-101	Calculated
MCH	30.7	pg	27-32	Calculated
MCHC	34	g/dL	31.5-34.5	Calculated
R.D.W	12.8	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,660	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (D	DLC)			
NEUTROPHILS	45.6	%	40-80	Electrical Impedance
LYMPHOCYTES	41.4	%	20-40	Electrical Impedance
EOSINOPHILS	5.4	%	1-6	Electrical Impedance
MONOCYTES	7.1	%	2-10	Electrical Impedance
BASOPHILS	0.5	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	2580.96	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2343.24	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	305.64	Cells/cu.mm	20-500	Calculated
MONOCYTES	401.86	Cells/cu.mm	200-1000	Calculated
BASOPHILS	28.3	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	175000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	2	mm at the end of 1 hour	0-15	Modified Westergrei
PERIPHERAL SMEAR		Of 1 Hour		

RBCs: are normocytic normochromic

WBCs: are normal in total number with normal distribution and morphology.

PLATELETS: appear adequate in number.

HEMOPARASITES: negative

Page 1 of 13











: Mr.JEEVAN DSOUZA

Age/Gender

: 36 Y 11 M 18 D/M

UHID/MR No

: CJPN.0000089496

Visit ID Ref Doctor : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected

: 25/Nov/2023 09:24AM

Received

: 25/Nov/2023 12:51PM : 25/Nov/2023 02:38PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE

Page 2 of 13



SIN No:BED230289605

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mr.JEEVAN DSOUZA

Age/Gender

: 36 Y 11 M 18 D/M

UHID/MR No

: CJPN.0000089496

Visit ID

: CJPNOPV181539

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 265801 Collected

: 25/Nov/2023 09:24AM

Received

: 25/Nov/2023 12:51PM : 25/Nov/2023 04:28PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

BI OO	D GROUP	ARO A	ND RH F	ACTOR	WHO! F B!	OOD FDTA

	OIL, MIOLE BLOOD LBIM	
BLOOD GROUP TYPE	0	Microplate
		Hemagglutination
Rh TYPE	Positive	Microplate
		Hemagglutination

Page 3 of 13

SIN No:BED230289605

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mr.JEEVAN DSOUZA

Age/Gender

: 36 Y 11 M 18 D/M

UHID/MR No

: CJPN.0000089496

Visit ID

: CJPNOPV181539

Ref Doctor Emp/Auth/TPA ID

: Dr.SELF : 265801 Collected

: 25/Nov/2023 12:38PM

Received

: 25/Nov/2023 05:19PM

Reported

: 25/Nov/2023 05:41PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

GLUCOSE, FASTING, NAF PLASMA	103	mg/dL	70-100	HEXOKINASE	
------------------------------	-----	-------	--------	------------	--

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	112	mg/dL	70-140	HEXOKINASE

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 4 of 13

SIN No:PLF02059609,PLP1390446 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





Method

Patient Name : Mr.JEEVAN DSOUZA
Age/Gender : 36 Y 11 M 18 D/M
UHID/MR No : CJPN.0000089496

Visit ID : CJPNOPV181539

Test Name

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM

Received : 25/Nov/2023 01:12PM

Reported : 25/Nov/2023 03:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

Bio. Ref. Range

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Unit

Result

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.8	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG), WHOLE BLOOD EDTA	120	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 13

SIN No:EDT230106098

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





Patient Name : Mr.JEEVAN DSOUZA Age/Gender : 36 Y 11 M 18 D/M

UHID/MR No : CJPN.0000089496 Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 01:50PM
Reported : 25/Nov/2023 03:52PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

			-	
ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUA	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

L IPID PROFILE , <i>SERUM</i>				
TOTAL CHOLESTEROL	190	mg/dL	<200	CHO-POD
TRIGLYCERIDES	97	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	48	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	142	mg/dL	<130	Calculated
LDL CHOLESTEROL	123.1	mg/dL	<100	Calculated
VLDL CHOLESTEROL	19.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.97		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
. D .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60	*		
INON-HOLCHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 13

SIN No:SE04550193

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mr.JEEVAN DSOUZA Age/Gender : 36 Y 11 M 18 D/M

UHID/MR No : CJPN.0000089496

Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801

Collected : 25/Nov/2023 09:24AM Received : 25/Nov/2023 01:50PM

Reported : 25/Nov/2023 03:52PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUAL	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.62	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.11	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.51	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	43	U/L	<50	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	32.0	U/L	<50	IFCC
ALKALINE PHOSPHATASE	70.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.23	g/dL	6.6-8.3	Biuret
ALBUMIN	5.14	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.09	g/dĹ	2.0-3.5	Calculated
A/G RATIO	2.46		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- · Disproportionate increase in AST, ALT compared with ALP.
- · Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 13







: Mr.JEEVAN DSOUZA

Age/Gender

: 36 Y 11 M 18 D/M

UHID/MR No Visit ID

: CJPN.0000089496

Ref Doctor

: CJPNOPV181539

: Dr.SELF Emp/Auth/TPA ID : 265801

Collected

: 25/Nov/2023 09:24AM

Received

: 25/Nov/2023 01:50PM : 25/Nov/2023 03:52PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name

Result

Unit

Bio. Ref. Range

Method

Page 8 of 13



NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telang www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744 na - 500 016 | APOLLO CLINICS NETWORK







: Mr.JEEVAN DSOUZA

Age/Gender

: 36 Y 11 M 18 D/M

UHID/MR No

: CJPN.0000089496

Visit ID

: CJPNOPV181539

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 265801

Collected

: 25/Nov/2023 09:24AM

Received

: 25/Nov/2023 01:50PM

Reported

: 25/Nov/2023 03:52PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM				
CREATININE	0.82	mg/dL	0.72 – 1.18	JAFFE METHOD
UREA	35.00	mg/dL	17-43	GLDH, Kinetic Assay
BLOOD UREA NITROGEN	16.4	mg/dL	8.0 - 23.0	Calculated
URIC ACID	6.46	mg/dL	3.5–7.2	Uricase PAP
CALCIUM	9.70	mg/dL	8.8-10.6	Arsenazo III
PHOSPHORUS, INORGANIC	3.54	mg/dL	2.5-4.5	Phosphomolybdate Complex
SODIUM	140	mmol/L	136–146	ISE (Indirect)
POTASSIUM	4.9	mmol/L	3.5–5.1	ISE (Indirect)
CHLORIDE	104	mmol/L	101–109	ISE (Indirect)

Page 9 of 13



SIN No:SE04550193

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mr.JEEVAN DSOUZA

Age/Gender

: 36 Y 11 M 18 D/M

UHID/MR No

: CJPN.0000089496

Visit ID Ref Doctor : CJPNOPV181539

: Dr.SELF

: 265801

Emp/Auth/TPA ID

Collected

: 25/Nov/2023 09:24AM

Received

: 25/Nov/2023 01:50PM : 25/Nov/2023 03:51PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

GAMMA GLUTAMYL TRANSPEPTIDASE	26.00	U/L	<55	IFCC	
(GGT) , SERUM					

Page 10 of 13



SIN No:SE04550193

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK







Patient Name : Mr.JEEVAN DSOUZA Age/Gender : 36 Y 11 M 18 D/M

UHID/MR No : CJPN.0000089496 Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801

 Collected
 : 25/Nov/2023 09:24AM

 Received
 : 25/Nov/2023 12:54PM

 Reported
 : 25/Nov/2023 05:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUA	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324	
Test Name	Result	Unit	Bio. Ref. Range	Method	

THYROID PROFILE TOTAL (T3, T4, TSH) , :	SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.1	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	6.50	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	6.526	μIU/mL	0.34-5.60	CLIA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 13

SIN No:SPL23167665

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK







: Mr.JEEVAN DSOUZA

Age/Gender

: 36 Y 11 M 18 D/M

UHID/MR No

: CJPN.0000089496

Visit ID

: CJPNOPV181539

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 265801

COMPLETE LIDING EVAMINATION (CHE) LIDING

Collected

: 25/Nov/2023 09:24AM

Received

: 25/Nov/2023 02:32PM

Reported

: 25/Nov/2023 04:55PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	6.0		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	OUNT AND MICROSCOPY			
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 13

SIN No:UR2226879

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK







: Mr.JEEVAN DSOUZA

Age/Gender

: 36 Y 11 M 18 D/M

UHID/MR No

: CJPN.0000089496

Visit ID

: CJPNOPV181539

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 265801

Collected

: 25/Nov/2023 09:24AM

Received

: 25/Nov/2023 02:32PM

Reported

: 25/Nov/2023 04:53PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

URINE GLUCOSE(POST PRANDIAL)

NEGATIVE

NEGATIVE

URINE GLUCOSE(FASTING)

NEGATIVE

NEGATIVE

Dipstick

Dipstick

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

DR. SHIVARAJA SHETTY M.B.B.S,M.D(Biochemistry) CONSULTANT BIOCHEMIST

Dr. Shobha Emmanuel M.B.B.S, M.D(Pathology) Consultant Pathologist

inki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist

Page 13 of 13



SIN No:UPP015840,UF009851 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE



Name : Mr. Jeevan Dsouza

Age: 36 Y

Sex: M

Address: blr

Plan

: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN

INDIA OP AGREEMENT

UHID:CJPN.0000089496

OP Number:CJPNOPV181539 Bill No :CJPN-OCR-67260

Date : 25.11.2023 09:19

Sno	Serive Type/ServiceName	Department
1	ARCOEEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PA	AN INDIA - FY2324
	I URINE GLUCOSE(FASTING)	
	2 GAMMA GLUTAMYL TRANFERASE (GGT)	
-	3 HbATc, GLYCATED HEMOGLOBIN	
9	42 DECHO ON TMT	
	5 LEVER FUNCTION TEST (LFT)	
	6X-RAY CHEST PA	
	7 GLUCOSE, FASTING	
	8 HEMOGRAM + PERIPHERAL SMEAR	
Ľ	9 ENT CONSULTATION	
1	0 FITNESS BY GENERAL PHYSICIAN	
1	I DIET CONSULTATION	
-1	2 COMPLETE URINE EXAMINATION	
	3 URINE GLUCOSE(POST PRANDIAL)	
1	4 PERIPHERAL SMEAR	
ل	s E eG	
ل	6 BLOOD GROUP ABO AND RH FACTOR	
1	7 LHPID PROFILE	
1	8 BODY MASS INDEX (BMI)	
Ţ	9 OPTHAL BY GENERAL PHYSICIAN	
2	PRENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
2	ULTRASOUND - WHOLE ABDOMEN	
2	2 FHYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	
-2	DENTAL CONSULTATION	
2	4 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)	

Ardio -21

B. p-131/88 m/Hg. Wet-80-7/g Het-164c.n Pause-1126/ny





Name - Jeevan døgou 2a Age - 36 gul m

Date - 25/11/23

Height :	Weight:	BMI:	Waist Circum:	
Temp :	Pulse :	Resp:	B.P:	

General Examination / Allergies History

Clinical Diagnosis & Management Plan

do- Rouline

Alo PUN- NO

410 Eye 8x - No

04 VM < 8/1 NO

Comelinessi

usion is mount in BE

Follow up date:

offer 6 months

Doctor Signature





Jeevan Doonza.
36/M.

25/11/2023

Height:	Weight:	BMI:	Waist Circum:
Temp :	Pulse :	Resp:	B.P:

General Examination / Allergies History

No DM HTN.

Clinical Diagnosis & Management Plan

- ENT check

- Nasal obstruction: - 1 Dung mercise &
Steep.

Cuom DNS + (L

Th/ Car. NAO.


Revins ses


Follow up date:

Doctor Signature

25-Nov-2023 12:35:40			2	MUUTU LY AR	Vay His Sinom XS of max predicted 184hpm	X Petalpate	4 hom		10 0 mm/mV
12:35:40	36years As 164cm 80	Asian Male 80kg	: X &	Max BP: 150/88 Reason for Termi	nation:	Maximum workload:	jg.	10.1METS	100hz
		0	SXX	Comments: GOOD EFFORT AND TOLERENCE NORMAL BP/HR RESPONSE NO ANGLINA AND ARRYTHMIA NOTED	D EFFORT AI RESPONSE O ARRYTHMI	ND TOLERE A NOTED	NCE		
_	Referred by: SELF, TAB ATORVA Test ind: CAD SCREENING	B ATORVA VING	× E	NO SIGNIFICANT ST-T CHANGES SEEN TMT IS NEGATIVE FOR INDUCIBLE ISCHEMIA	r st-t chan ve for indu	GES SEEN JUIBLE ISCI	HEMIA		
Phase Name	Stage Name	Time in Stage	Speed (mph)	Grade (%)	WorkLoad (METS)	HR (bpm)	BP (mmHg)	RPP (x100)	
PRETEST	SUPINE	0.5 86	8.0	0.0	7.3	105	130/88	137	
EXERCISE	STAGE 1	3:00	1.7	0.0.	;c;	132	:40/88	175	
	STAGE 2	3:00	2.5	13.0	0.7	87.	140/88	200	
	STAGE 3	3:00	3.4	14.0	10.1	# <u>10</u>	150/88	236	
RECOVERY	Post	1:48	*.	*. *	5.0	115	130/88	150	
				Noppost	1 89				
				4	}				
				î (
				78	(41)				
The bosiness BATRSHWARI	REHWARI				homari anari				
recullificall. IVS	т			2	D		MA	MAC55 010A	
		AB.	ARROW CE						

164cm	Asiaa PR interval 156 ms 80kg QRS duration 76 ms QT/QTc 326/436 ms P-R-T axes 67 81 26	156 ms 76 ms 26/436 ms 67 81 26	Otherwise normal ECG		
	Technician: RAJESHWARI Test ind: CAD SCREENING		Visit: AHC		
			Referred by: SELF, TAB ATORVA	Unconfirmed	
		aVR		7	
} 5		aVL		} } } } }	
		aVF	Nex Next	9 ₀	
15					
					\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
25.	25.3 mm/s 10.0 mm/mV		4 by 2.5s + 3 rhythm lds		





25-Nov-2023	35) vars	Asian 80kg	Male N	Max E.R. 157bpm 85% of max predicted 184bpm Max EP: 150/88 Reasor for Terrination: Comments: GOOD EFFORT AND TOLERENCE NORMAL BP/HR RESPONSE NORMAL BP/HR RESPONSE	max predicted 184bpm Maximum workload: ORT AND TOLERENCE NSE THMIA NOTED	pm cload: 10.1METS CE	.0.0 mm/mV .00hz
	Referred by: SELF, TAB ATORVA Test ad: CAD SCREENING	REENING	7. x £	NO SERNIFECANT ST-T CHANGES SEEN FINT IS NEGATIVE FOR INDECIBLE ISCHEMIA	CHANGES SEEN	SMIA	
3.5. BILINE DNE RCISE	MAX ST EXERCISE	PEAK EXERCISE	TEST END RECOVERY	BASEHINE EXARCISE F-00	MAX ST EXERCISE 8:44	PEAK EXERCISE 9:00	TEST END RECOVERY 1:48
105bpm 32: 150/88	8:44 156bpm BP: 150/88	157bpm B2: 150/88	115bpm BP: 130/88	105bm BP: 1:0/88	156bpm BP: 150/88	157bpm 3P: 150/88	11.55pm BP: 130/88
\ \ \ \ \	- }	7		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	}	\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	V1 V1
	10 / 10 / 10 / 10 / 10 / 10 / 10 / 10 /	- +8	9.7	7.8	5-1	\$53 (1.2	7.5 (.1)
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \					\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	V2 2.2 1.2 1.2
	\ 			\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			
	8.8	aV3	aVR -0.4		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	V4 V	X4
	a) []	aVI.		V 7: 1		\$ 50 50 7 50 7 50 7 50 7 50 7 50 7 50 7 5	7 07 T:
\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	a	ave	aVE	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Ve	V6
Technician: RAJESHWARI	AJESHWARI			Unconfirmed	ęg	M4(55 010A	Lead ST(mm) Stope(mV/s)

1D: CJITN89430 Visit: AHC 25-Nov-2023 12:35:40	36years 164cm	Asian Male 80kg	Max HR: 157bpn Max BP: 150/88 Max BP: 150/88 Reason for Term Comments: GOC	Max BP: 157bpm 85% of max Max BP: 150/88 Reason for Termination: Comments: GOOD EFFORT A NORMAL BP/HR RESPONSE	Max HR: 157bpm 85% of max predicted 184bpm Max BP: 150/88 Reason for Termination: Comments: GOOD EFFORT AND TOLERENCE	10.1METS	10.0 mm/mV 100hz
	Referred by: SEL Test ind: CAD SC	Referred by: SELF, TAB ATORVA Test ind: CAD SCREENING	NO ANG NO SIGN *	NO ANGINA AND ARRYTHMIA NOTED NO SIGNIFICANT ST-T CHANGES SEEN * TMT IS NEGATIVE FOR INDUCIBLE IS	NO ANGINA AND ARRYTHMIA NOTED NO SIGNIFICANT ST-T CHANGES SEEN * TMT IS NEGATIVE FOR INDUCIBLE ISCHEMIA		
EXERCISE STAGE 0:00 1.2ME'	BASELIN 1 FS	IE 105bpm ST @ 10mm/mV BP: 130/88 80ms postJ	Lead ST(mm) Slope(mV/s)	EXERCISE STA 8:44 10.1	MAX ST STAGE 3 156bpm 10.1METS BP: 150/88	ST @ 10mm/mV 88 80ms postJ	Lead ST(mm) Slope(mV/s)
0.5	aVR -0.5	V1 0.6 -0.1	1.3 1.0 1.0	0.5	aVR 0.0 -1.7	V1 -	V4 0.3 1.5
0.4	aVI. 0.6 0.1	V2 2.0 1.1	V5 V5 0.4 0.7		aVL 0.9 0.3	V22	V5 -1:0 -1:0 -0:3
0.00	aVR 0.0 0.5	V3 2.0 1.2	V6 0.0 0.5 0.0	11.9 6.0	aVF -1.4 1.4	V3 V3 2.6 2.9	7.0- 4.0.
Technician: RAJESHWARI	JESHWARI			Unconfirmed		MAC55 010A	



प्रति,

समन्वयक,

Mediwheel (Arcofemi Healthcare Limited)

हेल्पलाइन नंबर: 011-41195959

महोदय/ महोदया,

विषय: बैंक ऑफ़ बड़ौदा के कर्मचारियों के लिए वार्षिक स्वास्थ्य जांच।

हम आपको सूचित करना चाहते हैं कि हमारे कर्मचारी की पत्नी/पति जिनके विवरण निम्नानुसार हैं हमारे करार के अनुसार आपके द्वारा उपलब्ध कराई गई कैशलेस वार्षिक स्वास्थ्य जांच सुविधा का लाभ लेना चाहते हैं।

	स्वास्थ्य जांच लाभार्थी केविवरण
	JEROME JEEVANDSOUZA
नाम	07-12-1986
जन्म की तारीख	25-11-2023
कर्मचारी की पत्नी/पति के स्वास्थ्य जांच की प्रस्तावित तारीख	
ी नंदर्भ में	23D199572100074548S
बुकिंग संदर्भ सं.	पत्नी/पति केविवरण
	MS. REGO RENISHA GLORIA
कर्मचारी का नाम	100572
कर्मचारी की क.कूसंख्या	SINGLE WINDOW OPERATOR A
कर्मचारी का पद	BANGALORE,BANNERGHATTA
कर्मचारी के कार्य का स्थान	
कर्मचारी के जन्म की तारीख	29-08-1989

यह अनुमोदन/ संस्तुति पत्र तभी वैध माना जाएगा जब इसे बैंक ऑफ़ बड़ौदा के कर्मचारी आईडी कार्ड की प्रति के साथ प्रस्तुत किया जाएगा। यह अनुमोदन पत्र दिनांक 07-11-2023 से 31-03-2024 तक मान्य है। इस पत्र के साथ किए जाने वाले चिकित्सा जांच की सूची अनुलग्नक के रूप में दी गई है। कृपया नोट करें कि उक्त स्वास्थ्य जांच हमारी टाई-अप व्यवस्था के अनुसार कैशलेस सुविधा है। हम अनुरोध करते हैं कि आप हमारे कर्मचारी के पत्नी/पति की स्वास्थ्य जांच संबंधी आवश्यकताओं पर उचित कार्रवाई करें तथा इस संबंध में अपनी सर्वोच्च प्राथमिकता तथा सर्वोत्तम संसाधन उपलब्ध कराएं। उपर्युक्त सारणी में दी गई कर्मचारी कूट संख्या एवं बुकिंग संदर्भ संख्या का उल्लेख अनिवार्य रूप से इनवॉइस में किया जाना चाहिए।

हम इस संबंध में आपके सहयोग की अपेक्षा करते हैं।

भवदीय,

हस्ता/-

(मुख्य महाप्रबंधक)

मानव संसाधन प्रबंधन विभाग

बैंक ऑफ़ बड़ौदा

(नोट: यह कंप्यूटर द्वारा जनरेट किया गया पत्र है। हस्ताक्षर की आवश्यकता नहीं है। कृपया किसी भी रूपष्टीकरण के लिए Mediwheel (Arcofemi Healthcare Limited)से संपर्क करें।)






ಭಾರತ ಸರ್ಕಾರ Government of India

ಭಾರತೀಯ ವಿಶಿಷ್ಟ ಗುರುತು ಪ್ರಾಧಿಕಾರ Unique Identification Authority of India

ನೋಂದಣೆ ಸಂಖ್ಯೆ/ Enrolment No.: 0000/00800/58165

To ಜರೋಮ ಜೀವನ ಡಿರೋಜಾ Jerome Jeevan Dsouza No 110 A Block 1st Floor Sai Samraksha SY No 54/4 Yelenahalli Bangalore South Bengaluru Karnataka - 560068 9626375170

Signature valid



ನಿಮ್ಮ ಆಧಾರ್ ಸಂಖ್ಯೆ / Your Aadhaar No. :

2111 3453 0829 VID: 9183 6096 2678 1597

ನನ್ನ ಆಧಾರ್. ನನ್ನ ಗುರುತು



ಭಾರತ ಸರ್ಕಾರ Government of India



ಜರೋಮ ಜೀವನ ಡಿಸೋಜಾ Jerome Jeevan Dsouza ಜನ್ನ ದಿನಾಂಕ/DOB: 07/12/1986 ಪ್ರರುಷ/ MALE

2111 3453 0829

WD: 9183 6096 2678 1597 ನ್ನ ಆಧಾರ್. ನನ್ನ ಗುರುತು

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 265801

Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 12:51PM
Reported : 25/Nov/2023 02:38PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	15.5	g/dL	13-17	Spectrophotometer
PCV	45.50	%	40-50	Electronic pulse & Calculation
RBC COUNT	5.04	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	90.4	fL	83-101	Calculated
MCH	30.7	pg	27-32	Calculated
MCHC	34	g/dL	31.5-34.5	Calculated
R.D.W	12.8	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,660	cells/cu.mm	4000-10000	Electrical Impedanc
DIFFERENTIAL LEUCOCYTIC COUNT (D	DLC)			
NEUTROPHILS	45.6	%	40-80	Electrical Impedanc
LYMPHOCYTES	41.4	%	20-40	Electrical Impedanc
EOSINOPHILS	5.4	%	1-6	Electrical Impedanc
MONOCYTES	7.1	%	2-10	Electrical Impedanc
BASOPHILS	0.5	%	<1-2	Electrical Impedanc
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	2580.96	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2343.24	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	305.64	Cells/cu.mm	20-500	Calculated
MONOCYTES	401.86	Cells/cu.mm	200-1000	Calculated
BASOPHILS	28.3	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	175000	cells/cu.mm	150000-410000	Electrical impedenc
ERYTHROCYTE SEDIMENTATION RATE (ESR)	2	mm at the end	0-15	Modified Westergre

RBCs: are normocytic normochromic

WBCs: are normal in total number with normal distribution and morphology.

PLATELETS: appear adequate in number.

HEMOPARASITES: negative

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 12:51PM
Reported : 25/Nov/2023 02:38PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 12:51PM
Reported : 25/Nov/2023 04:28PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	HAEMATOLOG	Υ	
ARCOFEMI - MEDIWHEEL - I	FULL BODY ANNUA	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA						
BLOOD GROUP TYPE	0	Microplate Hemagglutination				
Rh TYPE	Positive	Microplate Hemagglutination				



Patient Name : Mr.JEEVAN DSOUZA
Age/Gender : 36 Y 11 M 18 D/M
UHID/MR No : CJPN.0000089496

Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 12:38PM
Received : 25/Nov/2023 05:19PM
Reported : 25/Nov/2023 05:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

GLUCOSE, FASTING, NAF PLASMA	103	mg/dL	70-100	HEXOKINASE	
------------------------------	-----	-------	--------	------------	--

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2	112	mg/dL	70-140	HEXOKINASE
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801

 Collected
 : 25/Nov/2023 09:24AM

 Received
 : 25/Nov/2023 01:12PM

 Reported
 : 25/Nov/2023 03:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

L	PEPARIMEN	I OF BIO	CHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324							
Test Name	Result	Unit	Bio. Ref. Range	Method			

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.8	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD EDTA	120	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 - 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 01:50PM
Reported : 25/Nov/2023 03:52PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ADCOFFMI MEDIMULEEL EULI DODY ANNUAL DILIC MALE OD ECUO DANIANDIA EVOSOA							
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324							
Test Name	Result	Unit	Bio. Ref. Range	Method			

190	mg/dL	<200	CHO-POD
97	mg/dL	<150	GPO-POD
48	mg/dL	40-60	Enzymatic Immunoinhibition
142	mg/dL	<130	Calculated
123.1	mg/dL	<100	Calculated
19.4	mg/dL	<30	Calculated
3.97		0-4.97	Calculated
	97 48 142 123.1 19.4	97 mg/dL 48 mg/dL 142 mg/dL 123.1 mg/dL 19.4 mg/dL	97 mg/dL <150 48 mg/dL 40-60 142 mg/dL <130 123.1 mg/dL <100 19.4 mg/dL <30

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.



Patient Name : Mr.JEEVAN DSOUZA Age/Gender : 36 Y 11 M 18 D/M UHID/MR No : CJPN.0000089496

Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 01:50PM
Reported : 25/Nov/2023 03:52PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

IVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.62	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.11	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.51	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	43	U/L	<50	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	32.0	U/L	<50	IFCC
ALKALINE PHOSPHATASE	70.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.23	g/dL	6.6-8.3	Biuret
ALBUMIN	5.14	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.09	g/dL	2.0-3.5	Calculated
A/G RATIO	2.46		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Patient Name : Mr.JEEVAN DSOUZA
Age/Gender : 36 Y 11 M 18 D/M
UHID/MR No : CJPN.0000089496
Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 01:50PM
Reported : 25/Nov/2023 03:52PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method



Patient Name : Mr.JEEVAN DSOUZA
Age/Gender : 36 Y 11 M 18 D/M
UHID/MR No : CJPN.0000089496
Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 01:50PM
Reported : 25/Nov/2023 03:52PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

RENAL PROFILE/KIDNEY FUNCTION T	EST (RFT/KFT) , SER	JM		
CREATININE	0.82	mg/dL	0.72 – 1.18	JAFFE METHOD
UREA	35.00	mg/dL	17-43	GLDH, Kinetic Assay
BLOOD UREA NITROGEN	16.4	mg/dL	8.0 - 23.0	Calculated
URIC ACID	6.46	mg/dL	3.5–7.2	Uricase PAP
CALCIUM	9.70	mg/dL	8.8-10.6	Arsenazo III
PHOSPHORUS, INORGANIC	3.54	mg/dL	2.5-4.5	Phosphomolybdate Complex
SODIUM	140	mmol/L	136–146	ISE (Indirect)
POTASSIUM	4.9	mmol/L	3.5–5.1	ISE (Indirect)
CHLORIDE	104	mmol/L	101–109	ISE (Indirect)



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 01:50PM
Reported : 25/Nov/2023 03:51PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method						
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT), SERUM	26.00	U/L	<55	IFCC		



Patient Name : Mr.JEEVAN DSOUZA Age/Gender : 36 Y 11 M 18 D/M

UHID/MR No : CJPN.0000089496

Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 12:54PM
Reported : 25/Nov/2023 05:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM							
TRI-IODOTHYRONINE (T3, TOTAL) 1.1 ng/mL 0.7-2.04 CLIA							
THYROXINE (T4, TOTAL)	6.50	μg/dL	5.48-14.28	CLIA			
THYROID STIMULATING HORMONE (TSH)	6.526	μIU/mL	0.34-5.60	CLIA			

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions	
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis	
High	N	N	N	oclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement erapy.	
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism	
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy	
Low	N	N	N	Subclinical Hyperthyroidism	
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism	
Low	N	High	High	Thyroiditis, Interfering Antibodies	
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes	
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801

 Collected
 : 25/Nov/2023 09:24AM

 Received
 : 25/Nov/2023 02:32PM

 Reported
 : 25/Nov/2023 04:55PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (C	UE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	OUNT AND MICROSCOPY			
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY



Patient Name : Mr.JEEVAN DSOUZA
Age/Gender : 36 Y 11 M 18 D/M
UHID/MR No : CJPN.0000089496
Visit ID : CJPNOPV181539

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265801 Collected : 25/Nov/2023 09:24AM
Received : 25/Nov/2023 02:32PM
Reported : 25/Nov/2023 04:53PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick		
ORINE GEOGGE(FOOT FRANDIAE)	NEOATIVE		NEGATIVE	Dipolick		
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dipstick		

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

DR.SHIVARAJA SHETTY
M.B.B.S,M.D(Biochemistry)
CONSULTANT BIOCHEMIST

Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist Dr. Chinki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist

